Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2008

01-12-2008 | Short Report

Quality of life in noncompliant adults with phenylketonuria after resumption of the diet

Authors: M. Bik-Multanowski, B. Didycz, R. Mozrzymas, M. Nowacka, L. Kaluzny, W. Cichy, B. Schneiberg, J. Amilkiewicz, A. Bilar, M. Gizewska, A. Lange, E. Starostecka, A. Chrobot, B. I. Wojcicka-Bartlomiejczyk, A. Milanowski

Published in: Journal of Inherited Metabolic Disease | Special Issue 2/2008

Login to get access

Summary

Background:

Discontinuation of dietary therapy in adults with phenylketonuria can lead to neuropsychological abnormalities and emotional problems. The aim of our study was to assess the change in quality of life in adult patients returning to the diet and to define the reasons for failure in diet resumption.

Methods:

Quality of life was assessed by means of the Psychological General Well-Being Index before study entry and subsequently after 3 and 9 months. Reasons for failure in diet resumption were analysed.

Results:

53 patients participated in the study. Initial quality of life assessment revealed severe distress in 17%, moderate distress in 28% and positive well-being in 55% of them. In the majority of patients with severe or moderate distress, improvement of subjective well-being was observed (especially in the domains of anxiety and depressiveness) if they managed to return to the diet (blood phenylalanine concentrations before study entry 0.78–1.62 mmol/L, mean 1.16 mmol/L; average blood phenylalanine concentration decrease by 0.42 mmol/L). Only 29 persons managed to maintain the diet for at least 3 months and only 10 participants finished the entire 9-month study protocol. Problems with dietary treatment while at work, the high cost of low-protein products and poor knowledge regarding proper diet were the most important factors responsible for failure in resumption of diet.

Conclusion:

Interpersonal differences exist between adult patients on relaxed diet, in some of whom quality of life often remains good, while others can suffer from severe emotional distress. Returning to diet increases quality of life in the majority of patients.
Literature
go back to reference Davison AN (1973) Inborn errors of amino acid metabolism affecting myelination of the central nervous system. In: Hommes FA, Van Den Berg CJ (eds). Inborn Errors of Metabolism. London: Academic Press, 55–67. Davison AN (1973) Inborn errors of amino acid metabolism affecting myelination of the central nervous system. In: Hommes FA, Van Den Berg CJ (eds). Inborn Errors of Metabolism. London: Academic Press, 55–67.
go back to reference Dupuy H (1984) The psychological general well-being (PGWB) index. In: Wenger N, et al. (eds). Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York, NY: Le Jacq Publishing Inc., 170–183. Dupuy H (1984) The psychological general well-being (PGWB) index. In: Wenger N, et al. (eds). Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York, NY: Le Jacq Publishing Inc., 170–183.
go back to reference Simon E, Schwarz M, Roos J, et al (2008) Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health and Quality of Life Outcomes 6: 25. doi:10.1186/1477-7525-6-25.PubMedCrossRef Simon E, Schwarz M, Roos J, et al (2008) Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health and Quality of Life Outcomes 6: 25. doi:10.​1186/​1477-7525-6-25.PubMedCrossRef
Metadata
Title
Quality of life in noncompliant adults with phenylketonuria after resumption of the diet
Authors
M. Bik-Multanowski
B. Didycz
R. Mozrzymas
M. Nowacka
L. Kaluzny
W. Cichy
B. Schneiberg
J. Amilkiewicz
A. Bilar
M. Gizewska
A. Lange
E. Starostecka
A. Chrobot
B. I. Wojcicka-Bartlomiejczyk
A. Milanowski
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 2/2008
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0978-7

Other articles of this Special Issue 2/2008

Journal of Inherited Metabolic Disease 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine